US9669088B2ActiveUtilityA1

Vaccination with multiple clades of H5 influenza A virus

68
Assignee: PODDA AUDINOPriority: Nov 26, 2007Filed: Nov 25, 2008Granted: Jun 6, 2017
Est. expiryNov 26, 2027(~1.4 yrs left)· nominal 20-yr term from priority
Inventors:Audino PoddaRino Rappuoli
A61P 31/16A61P 37/00A61K 2039/55566A61K 2039/53A61K 2039/5256A61K 2039/5258C07K 14/11C12N 2710/10343C12N 2760/16134A61K 2039/545A61K 39/12A61K 39/145C07K 14/115A61K 39/155
68
PatentIndex Score
1
Cited by
82
References
24
Claims

Abstract

H5N1 influenza viruses isolated from animals and humans since 2003 separate into distinct clades based on hemagglutinin amino acid sequences. According to the invention, multiple clades are used in influenza immunization. Thus there is a prime-boost immunization schedule where a subject receives a priming dose of a first clade of H5 influenza A virus and a boosting dose of a second clade of H5 influenza A virus. There is also an immunogenic composition comprising hemagglutinin antigens from more than one clade of H5 influenza A virus.

Claims

exact text as granted — not AI-modified
The invention claimed is: 
     
       1. A method for immunizing a patient, the method comprising a step of: administering to the patient an immunogenic composition comprising a hemagglutinin antigen from a second clade of H5 influenza A virus,
 wherein the patient was previously immunized with an adjuvanted influenza vaccine comprising a hemagglutinin antigen from a first clade of H5 influenza A virus; 
 wherein the adjuvanted influenza vaccine comprises an oil-in-water emulsion; 
 and wherein the first and the second clades are different. 
 
     
     
       2. The method of  claim 1 , wherein the immunogenic composition comprises 15 μg, 7.5 μg, or 3.75 μg hemagglutinin antigen from the second clade of H5 influenza A virus. 
     
     
       3. The method of  claim 1 , wherein the patient was immunized with the adjuvanted influenza vaccine comprising the hemagglutinin antigen from the first clade of H5 influenza A virus at least 9 months, at least 12 months, at least 18 months, at least 24 months, at least 36 months, at least 48 months or at least 60 months previously. 
     
     
       4. The method of  claim 1 , where the first clade is clade 1 and the second clade is clade 2. 
     
     
       5. The method of  claim 1 , where the first clade is clade 2 and the second clade is clade 1. 
     
     
       6. The method of  claim 1 , where the first clade is clade 1 and the second clade is not clade 2. 
     
     
       7. The method of  claim 1 , where the first clade is clade 2 and the second clade is not clade 1. 
     
     
       8. The method of  claim 1 , wherein the immunogenic composition and/or the adjuvanted influenza vaccine is a split vaccine. 
     
     
       9. The method of  claim 1 , wherein the immunogenic composition and/or the adjuvanted influenza vaccine is a purified subunit vaccine. 
     
     
       10. The method of  claim 1 , wherein the immunogenic composition and/or the adjuvanted influenza vaccine includes influenza A virus neuraminidase. 
     
     
       11. The method of  claim 1 , wherein the immunogenic composition comprising the second clade antigen is adjuvanted with an oil-in-water emulsion-adjuvant. 
     
     
       12. A method for immunizing a patient, the method comprising steps of:
 (i) administering to the patient a first influenza vaccine comprising a hemagglutinin antigen from a first clade of H5 influenza A virus and an oil-in-water emulsion; and 
 (ii) administering to the patient a second influenza vaccine comprising a hemagglutinin antigen from a second clade of H5 influenza A virus; 
 wherein the first and the second clades are different. 
 
     
     
       13. The method of  claim 12 , wherein the influenza vaccine comprises 15 μg, 7.5 μg, or 3.75 μg hemagglutinin antigen from the second clade of H5 influenza A virus. 
     
     
       14. The method of  claim 12 , wherein the influenza vaccine comprising the hemagglutinin antigen from the first clade of H5 influenza A virus is administered at least 9 months, at least 12 months, at least 18 months, at least 24 months, at least 36 months, at least 48 months or at least 60 months before administration of the influenza vaccine comprising the hemagglutinin antigen from the second clade of H5 influenza A virus. 
     
     
       15. The method of  claim 12 , where the first clade is clade 1 and the second clade is clade 2. 
     
     
       16. The method of  claim 12 , where the first clade is clade 2 and the second clade is clade 1. 
     
     
       17. The method of  claim 12 , where the first clade is clade 1 and the second clade is not clade 2. 
     
     
       18. The method of  claim 12 , where the first clade is clade 2 and the second clade is not clade 1. 
     
     
       19. The method of  claim 12 , wherein the first and/or the second influenza vaccine is a split vaccine. 
     
     
       20. The method of  claim 12 , wherein the first and/or the second influenza vaccine is a purified subunit vaccine. 
     
     
       21. The method of  claim 12 , wherein the first and/or the second influenza vaccine includes influenza A virus neuraminidase. 
     
     
       22. The method of  claim 12 , wherein the influenza vaccine comprising the second clade antigen is adjuvanted with an oil-in-water emulsion adjuvant. 
     
     
       23. The method of  claim 1 , wherein the immunogenic composition comprises <15μg hemagglutinin antigen from the second clade of H5 influenza A virus. 
     
     
       24. The method of  claim 12 , wherein the influenza vaccine comprises <15μg hemagglutinin antigen from the second clade of H5 influenza A virus.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.